Table 3 Response to therapeutic DLI

From: Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect

Variables No/short post DLI prophylaxis, n=18 Long (that is, greater than 2 weeks), n=13 P-value
Diagnosis, no.    0.10
 AML 6 2  
Primary induction failure 3   
Untreated or refractory relapse 1   
CR2 2 2  
 ALL 7 2  
Primary induction failure 4 1  
CR2 3 1  
 CML 5 9  
Chronic phase 2 6  
Accelerated/blastic phase 3 3  
Disease status, no.    0.15
 Standard risk 7 9  
 High risk 11 4  
Duration from HSCT to relapse, d    0.20
 Median (Range) 68 (25–710) 186 (20–1751)  
Patients with intervention or not 0.696
 With intervention 12 (chemo 7 +ima 5) 10 (chemo 1+ima 9)  
 Without intervention 6 3  
Follow-up time, months    0.09
 Median (range) 12 (1.9–199) 32 (1.8–79)  
Follow-up time in survivors, months 0.13
 No. of evaluable patients 4 12  
 Median (range) 55 (40–199) 35 (1.8–79)  
CR rate 7/18 10/13 0.04
CR patients with intervention 6/7 (chemo 4+ima 2) 9/10 (chemo 1+ima 8)  
Duration of CR (days) 488 (164–5864) 746 (111–1679) 0.29
5-year overall survival (%) 22 90 0.001
5-year leukaemia free survival (%) 17 55 0.003
  1. chemo: interfere with one of the following chemotherapies: (i) methotrexate, 1 g; (ii) arabinoside, 100 mg/m2/day for 7 days and daunorubicin, 40 mg/m2/day for 3 days; (iii) mitoxantrone, 4 mg/m2/day on days 1 and 4 and etoposide, 50 mg/m2/day for 5 days; and (iv) fludarabine, 30 mg/m2/day for 5 days or ima (imatinib, (300–400 mg/day) before DLI.